DVG Solutions
Close to 30 years of financial expertise working with private and publicly traded companies, offering a full suite of services ranging from financing transactions and strategic financial planning to transactional accounting.
-
IPOs
-
Mergers & acquisitions
-
Fundraising - equity & venture back/commercial debt offerings
-
Strategic/financial planning & budgeting
-
Investor/Board Communications
-
Technical accounting
-
GAAP financial statement preparation
-
Metrics/analysis/dashboards
-
Project management – ERP implementation, financial audits
-
Manage service providers – audit, payroll, legal, investor relations, banking, insurance, Sunshine Act, benefits administration
-
Build/manage accounting, finance, treasury, IT and customer service teams
Dan George, Managing Director
dgeorge@dvgsolutions.com | Phone: 415-860-2550
Dan is a seasoned financial professional with almost 30 years of experience. Most recently, Dan was the Chief Financial Officer of Lucira Health (LHDX), a decentralized molecular diagnostic company. Lucira's initial commercial product offering was focused on diagnosing COVID-19 and more recently launched a combination product that detects COVID-19, Flu A and Flu B with one test. During Dan's tenure as CFO, Lucira went public and sold close to $250 million in product revenue.
Prior to Lucira, Dan managed his financial consulting practice where he focused on servicing healthcare companies, specifically medtech. Dan performed activities from being a contract CFO to advising on specific transactions and projects. During this time, Dan engaged with over 25 clients that included the following acquisitions:
-
Brightwater Medical (Interventional Radiology) acquired by Merit Medical
-
Arrinex (ENT) acquired by Stryker
-
Iantech (Opthalmic) acquired by Carl Zeiss Meditec
-
Spirox (ENT) acquired by Entellus acquired by Stryker
Before launching his consulting practice, Dan served as Vice President of Finance for Avinger (AVGR), a company that develops and manufactures therapeutic devices that treat peripheral arterial disease by way of image-guided (Optical Coherence Tomography) atherectomy and chronic total occlusion crossing devices. Dan spearheaded the company's preparation for its successful public offering while managing the financial and customer service functions.
Prior to Avinger, Dan served as a consultant and Vice President of Finance for ApniCure, a venture-backed medical device company specializing in the treatment of sleep apnea. Prior to Apnicure, Dan worked for Avantis Medical Systems, a venture-backed manufacturer of visualization technology used injunction with colonoscopy where he was both a consultant and Chief Financial Officer. While at ApniCure and Avantis, Dan was responsible for the financial organizations and helped secure equity and debt financings. Also during his tenure, Dan provided financial consulting services for a number of other venture-backed medical device companies.
Prior to his time at Avantis, Dan was the Sr. Director of Finance at FoxHollow Technologies (FOXH aquired by EVVV; COV; MDT), a venture-backed company that developed atherectomy devices that treat peripheral arterial disease. Dan played an integral role in the company's public offering and ensured a scalable financial infrastructure and SOX compliance as the company experienced rapid commerical growth, increasing quarterly revenue from $3 million to over $40 million in less than 2 years.
Prior to FoxHollow, Dan worked for PricewaterhouseCoopers in the assurance and business advisory practice. Dan holds B.S. degrees in both Accounting and Finance from California State University, Long Beach.